Improve the Traditional CRO Experience with a Digital CRO

As a global full-service digital contract research organization (dCRO), Clinipace has pioneered an innovative service model to serve the unique needs of venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device firms.

Drug & Clinical Development

From managing your entire drug development program to conducting an individual clinical trial, our experts bring extensive therapeutic experience in building a well-defined strategy and clinical plan to maximize the success of your drug candidate. Our clinical teams can help operationalize (affordably) your protocol and provide much needed visibility into your studies.

  Read More Download Brochure

Regulatory & Strategic Development

Whatever the scale or complexity, we have the expertise to move your products from the lab to market while maximizing your success with regulatory authorities. Our consultants collaborate with your experts to construct a strategic plan along with a budgetary analysis so your program stays on track and your investors and stakeholders are well-informed.

  Read More Download Brochure

Medical Device Development

Between a push for comparative effectiveness research and new regulatory hurdles, good engineering no longer guarantees clinical development or commercial success. Introducing new devices has become more complex, but our experts help navigate the regulatory and clinical landscape in support of your PMA, 510(k), and CE mark application.

  Read More Download Brochure

The Power of the dCRO

Clinipace pioneered an innovative service model to transform drug and medical device development by delivering technology-amplified services to improve performance, collaboration, and visibility across all stakeholders.

Learn How

Clinical Research Studies

Consulting Engagements

Improve Your Trial Efficiency and Data Visibility Now

Contact Us

I just wanted to reach out to you and tell you how pleased I am with the randomization progress since we implemented the leads calling the sites either with subjects approaching day 60 or that had gone beyond day 60…If we continue to achieve the new average or better, the study should finish closer to our original goal…A giant thank you.

Christa Lee

AbbVie, Inc.

Not only was the cost reasonable, they were willing to offer flexibility in terms…The software deployed quickly, and the investigator sites love it…I’ve been in this industry a long time, and this is the first tool I’ve seen with the flexibility we needed to manage our research processes.

John Ely

On-X Life Technologies, Inc.

You took this study when we were knee deep in…and are responsible for the success that we have had with the Pivotal 1 study. We couldn’t have done it without you, and we continue to have success daily with the stellar team that we have been given to work with. You all are a pleasure to work with on a daily basis. You certainly make our jobs easier.

Julie Gavigan

AbbVie, Inc.